06.05.24
Nevada’s Division of Insurance (DOI) announced that it will require state-regulated health plans to apply manufacturer assistance to an enrollee’s cost-sharing obligations under a plan, except when a generic alternative is available
05.30.24
During its meeting on May 20, Maryland’s Prescription Drug Affordability Board (PDAB) unanimously voted to conduct cost reviews on six of eight products it was considering.
On May 17, the Senate Finance Committee released a long-awaited white paper describing its legislative effort focused on bolstering chronic care through physician payment.
On May 21, the U.S. Court of Appeals for the District of Columbia Circuit upheld the right of pharmaceutical manufacturers to place at least some restrictions on the shipment of 340B drugs to contract pharmacies of 340B covered entities.
05.29.24
Now, more than ever, health care organizations are facing complex antitrust issues as their mergers/acquisitions, hiring, contracting and private funding are being scrutinized by the federal and state governments.
05.23.24
The United States occupies a leadership position in clinical advancements, in terms of pharmaceuticals, medical devices, innovative care processes and interventional techniques.
05.22.24
Why Focus on Long-Term Services and Supports (LTSS) in Massachusetts?
On May 16, the House Energy and Commerce Health Subcommittee held a markup of 23 bills.
On May 13, an association of Medicare Advantage field marketing organizations (FMOs) filed suit against CMS, challenging new marketing restrictions in the 2025 Medicare Advantage final rule.
On May 15, the Centers for Medicare & Medicaid Services (CMS) issued a statement saying that it would not finalize the “stacking” proposal in its Medicaid Drug Rebate Program proposed rule—the remaining provisions are expected to be finalized soon.